Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MBX
stocks logo

MBX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker
Wall Street analysts forecast MBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBX is 64.00 USD with a low forecast of 45.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast MBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBX is 64.00 USD with a low forecast of 45.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 30.540
sliders
Low
45.00
Averages
64.00
High
80.00
Current: 30.540
sliders
Low
45.00
Averages
64.00
High
80.00
Goldman Sachs
Sell
initiated
$18
2025-12-04
New
Reason
Goldman Sachs
Price Target
$18
2025-12-04
New
initiated
Sell
Reason
Goldman Sachs initiated coverage of MBX Biosciences with a Sell rating and $18 price target. The key issue for MBX over the next year will be whether its platform shows validity beyond canvuparatide, with upcoming Phase 2a Post-Bariatric Hypoglycemia data in 2Q26 serving as the next major catalyst but likely falling short of demonstrating meaningful differentiation and driving a challenging risk/benefit profile, the analyst tells investors in a research note. While canvuparatide's long-term extension data appear relatively de-risked, and early-stage obesity data in 4Q26 could help validate the platform, these programs remain early, supporting a cautious outlook despite recent stock strength and potential upside from future business development, Goldman says.
Guggenheim
Buy
maintain
$84 -> $77
2025-11-10
Reason
Guggenheim
Price Target
$84 -> $77
2025-11-10
maintain
Buy
Reason
Guggenheim lowered the firm's price target on MBX Biosciences to $77 from $84 and keeps a Buy rating on the shares following Q3 earnings. The firm, which reiterates "Top Pick Designation" as MBX advances towards a catalyst-rich 2026, updated its model for Q3 results and the September financing, which drives its price target change.
Mizuho
Uy Ear
Outperform
maintain
$56 -> $57
2025-11-07
Reason
Mizuho
Uy Ear
Price Target
$56 -> $57
2025-11-07
maintain
Outperform
Reason
Mizuho analyst Uy Ear raised the firm's price target on MBX Biosciences to $57 from $56 and keeps an Outperform rating on the shares.
TD Cowen
initiated
2025-11-04
Reason
TD Cowen
Price Target
2025-11-04
initiated
Reason
TD Cowen initiated coverage of MBX Biosciences with a Buy rating and no price target. The firm believes the company's Prostate Secretory Protein platform is supported by "world-class chemistry with strong management." Canvuparatide exceeded high expectations with the recent Phase II hypoparathyroidism data, which provides conviction in Phase III success, the analyst tells investors in a research note. TD estimates peak sales of $2B.
Truist
Srikripa Devarakonda
Buy
initiated
$50
2025-10-14
Reason
Truist
Srikripa Devarakonda
Price Target
$50
2025-10-14
initiated
Buy
Reason
Truist analyst Srikripa Devarakonda initiated coverage of MBX Biosciences with a Buy rating and $50 price target. The firm is positive on the company's potential best-in-class de-risked lead asset canvuparatide with promising Phase 2 data in established endocrine disease and its second asset with potential for best-in-class, offering peak $810M and $230M opportunity in PBH and post-bariatric hypoglycemia respectively, the analyst tells investors in a research note. Truist adds that it sees 2036 peak unadjusted $3.2B sales estimated for canvuparatide, which the firm does not believe is reflected at current levels, noting however that this is an opportunity with a longer term outlook.
Mizuho
Outperform
maintain
$38 -> $56
2025-09-24
Reason
Mizuho
Price Target
$38 -> $56
2025-09-24
maintain
Outperform
Reason
Mizuho raised the firm's price target on MBX Biosciences to $56 from $38 and keeps an Outperform rating on the shares. The firm believes the Phase 2 trial of canvuparatide in hypoparathyroidism delivered on "lofty investor expectations with competitive data." Physicians Mizuho consulted see the potential for 30%-40% canvuparatide adoption even if the data is not as strong as daily Yorvipath's given canvuparatide's "differentiating" once-weekly injection, which cuts daily injection by 85% annually, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for MBX Biosciences Inc (MBX.O) is -9.62, compared to its 5-year average forward P/E of -5.56. For a more detailed relative valuation and DCF analysis to assess MBX Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-5.56
Current PE
-9.62
Overvalued PE
-3.09
Undervalued PE
-8.04

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.75
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.07
Undervalued EV/EBITDA
-5.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MBX News & Events

Events Timeline

(ET)
2025-12-04
16:20:00
Major Averages Close Little Changed as Jobless Claims Fall to 191,000
select
2025-12-04
12:00:00
Major U.S. Indices Little Changed as Investors Anticipate Fed Rate Cut
select
2025-12-04
09:00:00
Stock Futures Flat as Investors Await Economic Data
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-04Globenewswire
Microbix Initiates NCIB to Repurchase Up to 6.95 Million Shares
  • NCIB Launch: Microbix has announced the initiation of a Normal Course Issuer Bid (NCIB) to repurchase up to 6,949,346 shares, representing approximately 5% of the outstanding shares as of November 26, 2025, aiming to enhance shareholder value.
  • Market Operation Details: The repurchase will occur on the Toronto Stock Exchange over a 12-month period starting December 9, 2025, and ending December 8, 2026, or earlier upon completion, demonstrating the company's agility in responding to market conditions.
  • Funding and Strategy: The repurchase will be financed from working capital, and Microbix plans to use the NCIB to offset dilution from stock options exercised, thereby enhancing earnings per share.
  • Board Confidence: The Board believes that the current market price does not reflect the company's intrinsic value, and the share repurchase is expected to increase the equity interest of remaining shareholders, bolstering market confidence in the company's future growth.
[object Object]
Preview
7.5
12-03Globenewswire
Microbix Partners with Seegene to Enhance HPV Testing Quality
  • Quality Enhancement Partnership: Microbix's external third-party quality assessment products (QAPs®) will support Seegene Mexico's Allplex™ and Anyplex™ molecular assays, ensuring high quality and accuracy in HPV testing, thereby enhancing public health monitoring capabilities.
  • Technological Innovation: Seegene's Allplex HPV 28 detection assays identify 19 high-risk and 9 low-risk HPV genotypes, utilizing semi-quantitative data to provide infection status and genotype distribution information, significantly improving the effectiveness of early cancer screening.
  • Market Expansion: Microbix's QAPs are now sold in over 30 countries, supporting quality management in the global diagnostics industry, and are expected to further drive its penetration and influence in the Latin American market.
  • Public Health Commitment: Seegene Mexico's CEO stated that expanding access to HPV testing will significantly improve cervical cancer surveillance in Mexico, with Microbix's support accelerating the implementation and broad adoption of new testing platforms.
[object Object]
Preview
7.5
12-03Newsfilter
Microbix Partners with Seegene to Enhance HPV Testing Quality
  • Collaboration Enhances Testing Capability: Microbix partners with Seegene Mexico to utilize its external quality assessment products (QAPs®) in support of Allplex™ and Anyplex™ HPV molecular diagnostics, aiming to significantly improve cervical cancer screening efficiency in Mexico and enhance public health outcomes.
  • Technological Innovation Drives Market: Seegene's Allplex and Anyplex HPV 28 detection systems can simultaneously identify 19 high-risk and 9 low-risk HPV genotypes, providing semi-quantitative data that helps clinical labs meet international quality standards, thereby improving testing accuracy and reliability.
  • Rapid Training and Validation: By employing HPV-focused QAPs, Microbix ensures that new labs can undergo rapid training and validation, enabling them to quickly achieve high-standard testing capabilities, which will facilitate the widespread adoption of HPV testing.
  • Market Expansion Potential: Microbix plans to extend support beyond HPV testing to include respiratory, sexually transmitted, and other infectious disease diagnostics, demonstrating its broad application potential in molecular diagnostics and further enhancing its competitive position in the market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MBX Biosciences Inc (MBX) stock price today?

The current price of MBX is 30.54 USD — it has decreased -10.02 % in the last trading day.

arrow icon

What is MBX Biosciences Inc (MBX)'s business?

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.

arrow icon

What is the price predicton of MBX Stock?

Wall Street analysts forecast MBX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBX is 64.00 USD with a low forecast of 45.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MBX Biosciences Inc (MBX)'s revenue for the last quarter?

MBX Biosciences Inc revenue for the last quarter amounts to -23.93M USD, increased 22.00 % YoY.

arrow icon

What is MBX Biosciences Inc (MBX)'s earnings per share (EPS) for the last quarter?

MBX Biosciences Inc. EPS for the last quarter amounts to -21935000.00 USD, increased 49.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for MBX Biosciences Inc (MBX)'s fundamentals?

The market is revising No Change the revenue expectations for MBX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 164.42%.
arrow icon

How many employees does MBX Biosciences Inc (MBX). have?

MBX Biosciences Inc (MBX) has 43 emplpoyees as of December 05 2025.

arrow icon

What is MBX Biosciences Inc (MBX) market cap?

Today MBX has the market capitalization of 1.37B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free